Pfizer Corporation

Biopharma Works LLC

Systamedic Inc.

Ingenious Ingredients, LP

Anton F Fliri

Takushi Kaneko

Rodney C Schnur

Jotham Wadsworth Coe

Eric R Larson

Mark Allen Sanner

Robert A Volkmann

Brian Thomas O'Neill

Kishor A Desai

William Stephen Faraci

Stevin H Zorn

Shawn Wells

Martin Purpura

William T Loging

Ralf Jaeger

Kylin Lao

The disclosed compositions and methods relate to the increasing muscle mass, preventing muscle atrophy, promoting muscle growth, as well as treatment of various other conditions and diseases. In certain aspects, the disclosed compositions are comprised dileucine and leucine and pharmaceutically acceptable salts thereof. In certain aspects, disclosed compositions are administered to subjects in need thereof to increase muscle mass, prevent muscle atrophy, and/or promote muscle growth.

Compositions and methods of use thereof to promote muscle growth and function

The disclosed embodiments relate to data mining methods for determining economically valuable cause effect relationships between objects and properties associated with objects using co-occurrence frequency measurements of semantic terms characterizing observations of properties, effects or behaviors of objects in different environments and using these measurements as object descriptors in calculations determining object similarities. Specifically, these methods may be used to identify new indications of medicines, identify biomarkers associated with disease, identify biomarkers associated with drug effects, quantify disease diagnosis, identify novel drug targets, identify pharmacologic equivalencies of medicines, identify pharmacologic equivalencies between medicines and traditional medicines, identify pharmacologic equivalencies between medicines and Natural products, identify equivalencies between alternate medical procedures, identify risk benefit profiles of medicine combinations, identify targets for antibodies, identify synergies between medicines, identify Side effects of medicines, identify risks of experimental medicines, identify functions of biological networks.

Method of knowledge extraction through data mining

The present invention relates to novel biguanide derivatives including their pharmaceutically acceptable salts. The invention also relates processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions containing and the uses of such compounds in treating disorders such as diabetes.

Metformin derivatives

Substituted pyrido[1,2-a]pyrazines of general formula I; wherein Ar and Arrepresent various carbocyclic and heterocyclic aromatic rings; A represents O, S, SO, SO, CHOH, C&#x2550;O, or &#x2014;(CRR); and n is 0&#x2013;2, as well as precursors thereto, are ligands for dopamine receptor subtypes and serotonin (5HT) within the body and are therefore useful in the treatment of disorders of the dopamine and serotonin systems: 

2,7-substituted octahydro-1H-pyrido[1,2-a]pyrazine derivatives as ligands for serotonin receptors

Benzimidazole derivatives having dopaminergic activity

Benzimidazolone derivatives with central dopaminergic activity

2,7-substituted octahydro-1H-pyrido�1,2-a!pyrazine derivatives

Heterocyclic compounds for enhancing antitumor activity

Triazine derivatives for enhancing antitumor activity

Pyrimidine derivatives for enhancing antitumor activity

Quinazolines derivatives for enhancing antitumor activity

Acyl derivatives of 2-aminobenzothiazole and alkylated analogs thereof as antitumor agents.

Aromatic and heterocyclic carboxamide derivatives as antineoplastic

Compounds of the formula ##STR1## where Het is a heterocyclic group, n is an integer of 0 to 2 and R.sup.1 is hydrogen or lower alkyl are protease inhibitors useful as anti-plasmin and anti-thrombin agents.

Benzamide protease inhibitors

Compounds of the formula ##STR1## where HET is a heterocyclic group, n is an integer of 0 to 2 and R.sup.1 is hydrogen or lower alkyl are protease inhibitors useful as anti-plasmin and antithrombin agents.

Compounds of the formula ##STR1## where HET is a heterocyclic group, n is an integer of 0 to 2 and R.sup.1 is hydrogen or lower alkyl are protease inhibitors use as anti-plasmin and anti-thrombin agents.

Growing community of inventors

Norwich, CT, United States of America

Anton F Fliri